<div id="readability-page-1"><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Novo Nordisk A/S, Eli Lilly and Company, Bristol Myers Squibb, Pfizer,  and Dynavax Technologies are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and sell prescription drugs, vaccines and related pharmaceutical products. Their value to investors depends heavily on factors like drug pipelines, clinical trial results, regulatory approvals, patent protection and pricing/reimbursement dynamics, which can make the sector more cyclical and event-driven than the broader market. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Read Our Latest Research Report on NVO</p><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Bristol Myers Squibb (BMY)</h2><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><p>Read Our Latest Research Report on BMY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><p>Read Our Latest Research Report on PFE</p><h2>Dynavax Technologies (DVAX)</h2><p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p><p>Read Our Latest Research Report on DVAX</p><h2>Featured Articles</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>Why Kratos and AeroVironment Are Suddenly Moving Like Tech Stocks</li><li>Microsoft May Look Pricey, But Customers Can’t Walk Away</li><li>Oil’s Outlook Looks Ugly—That’s Why These 3 Energy Plays Matter</li><li>This ETF Will Benefit From Americans' Higher Energy Bills</li><li>From Lagging to Leading: FuelCell Energy’s Strategic Pivot</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>MarketBeat's stock screener tool highlights five pharmaceutical stocks to watch: Novo Nordisk, Eli Lilly, Bristol Myers Squibb, Pfizer, and Dynavax Technologies. These stocks have high trading volumes and are influenced by factors like drug pipelines and regulatory approvals. Analysts suggest these stocks have potential upside, though Novo Nordisk currently holds a 'Hold' rating. Investors should consider these stocks for potential gains.</p>

Pharmaceutical Stocks Worth Watching - December 25th